Roche’s Polivy Reverts To Standard Review In EU
US-approved r/r DLBCL treatment has lost its accelerated assessment status
Just two products are being assessed under the EMA's fast-track mechanism now that the marketing application for Roche's Polivy has reverted to standard review.
You may also be interested in...
Third Time Lucky for Roche’s Polivy in Europe?
It’s decision time again at the European Medicines Agency and Roche’s Polivy is one of the new drug applications that is up for a potential marketing recommendation.
EU Accelerated Assessment Tracker
The outcomes of six requests for accelerated assessment that companies have made for their planned marketing authorization applications in the EU are still unknown.
EMA OKs Seven New Drugs But Delivers Another Blow To Emmaus
Seven new drugs have this week moved closer to gaining EU approval following positive recommendations from the European Medicines Agency, but Emmaus’ glutamine product has fared less well and the company is considering another route for getting the drug to sickle cell disease patients in Europe